Gilead Sciences announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, showing that Trodelvy (sacituzumab govitecan-hziy) combined with Keytruda (pembrolizumab) significantly improves progression-free survival (PFS) in patients with previously untreated PD-L1 metastatic triple-negative breast cancer. The trial involved 443 patients and demonstrated a clinically meaningful improvement in PFS without introducing new safety concerns. While overall survival data is not yet mature, early trends indicate potential benefits. Detailed findings will be presented at future medical meetings. Trodelvy remains the only approved Trop-2-directed antibody-drug conjugate showing survival advantages in multiple breast cancer types.
— new from Gilead Sciences